Q&A: Novartis’ Eric Hughes on transplantationWith approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems Share XQ&A: Novartis’ Eric Hughes on transplantationhttps://pharmaphorum.com/r-d/views-analysis-r-d/novartis-eric-hughes-transplantation/
Smartphone screening project for kidney disease launched in the NetherlandsA project to screen 15,000 people aged between 45 and 80 using smartphone technology has started in the Share XSmartphone screening project for kidney disease launched in the Netherlandshttps://pharmaphorum.com/news/smartphone-screening-project-for-kidney-disease-launched-in-the-netherlands/
Calliditas pushing on with kidney disease drug after IPO successCalliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it Share XCalliditas pushing on with kidney disease drug after IPO successhttps://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/
Otsuka has high hopes for its ‘drug creation engine’ acquisitionOtsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug Share XOtsuka has high hopes for its ‘drug creation engine’ acquisitionhttps://pharmaphorum.com/news/otsuka-biotech-visterra-hierotope/
